东诚药业：225Ac-LNC1011注射液获临床试验批准

Core Viewpoint - Dongcheng Pharmaceutical announced that Yantai Lanna Biotechnology Co., Ltd. received clinical trial approval from the National Medical Products Administration for the 225Ac-LNC1011 injection, a targeted α-particle radiotherapy drug for treating advanced prostate cancer patients expressing PSMA [1] Company Summary - The 225Ac-LNC1011 injection has shown good pharmacokinetic properties and significant efficacy in completed animal and human trials, demonstrating effectiveness and precision in treating metastatic castration-resistant prostate cancer (mCRPC) [1] - The total research and development investment for this project has reached approximately 14.53 million yuan [1] Industry Summary - The approval for clinical trials indicates a potential advancement in the treatment options available for patients with advanced prostate cancer, particularly those with PSMA-positive expression [1] - The drug must undergo multiple phases of clinical trials and official reviews before it can be marketed and sold [1]